Guardant360 CDx
FDA premarket approval P200010/S021 · decided 2025-09-25
Approval details
- PMA number
- P200010
- Supplement
- S021
- Supplement type
- Panel Track
- Supplement reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Trade name
- Guardant360 CDx
- Generic name
- Next generation sequencing oncology panel, somatic or germline variant detection system
- Applicant
- Guardant Health, Inc.
- Date received
- 2024-11-04
- Decision date
- 2025-09-25
- Days to decision
- 325 days
- Decision code
- APPR
- Product code
- PQP
- Advisory committee
- Pathology
- Expedited review
- No
- Location
- Redwood City, CA
- Statement
- Approval for expanding the indications for use to include the companion diagnostic claim to identify breast cancer patients with specific ESR1 mutations for treatment with INLURIYO (imlunestrant).
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.